Samsung BioLogics sees sales rise but profit fall as it continues expansion | Fierce Pharma
Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
Samsung Biologics' focused approach pays off in 2020 - KED Global
Company News | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics Accelerates Timeline Of New Fifth Plant | Contract Pharma
Samsung Biologics' P4 Super Plant, Songdo, South Korea
Samsung Biologics eyes IPO by year-end - Nikkei Asia
Company News | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab | World Pharma Today
Samsung Biologics reports earnings surprise in Q2 on vaccine addition - Pulse by Maeil Business News Korea
Samsung Biologics | The Leading Global CDMO with End-to-End Services
Samsung Biologics signs $409 mil. CMO deal with Pfizer - The Korea Times
Samsung Biologics Plans to Accelerate the Opening of its New Fifth Plant
Samsung Biologics | Incheon
Samsung Biologics to double production by 2032; eyes ADCs, M&As - KED Global
Samsung Biologics Page 1 of 0 | ISM
Samsung Biologics set to start construction of Plant 5
Samsung Biologics reports an 18.8-percent rise in net profit
PharmaBoardroom - Samsung Biologics
Samsung Biologics Sets Sights on Net Zero Transition as New Plant Revs Up
Samsung Biologics to go big on CDMO at BIO USA 2023
Samsung BioLogics: The story of the world's largest biologics manufacturing facility
Samsung BioLogics Plant 3 Starts Production
Samsung Biologics Aims to Create Super-wide Gap in CDMO Field - Businesskorea
Samsung Biologics' P4 Super Plant, Songdo, South Korea
Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B | BioWorld
Pfizer and Samsung Biologics ink biosimilars manufacturing deal
Samsung Biologics acquires Samsung Bioepis joint venture for $2.3bn
